During the 66th ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari about the latest updates from the inMIND trial of tafasitamab plus lenalidomide and rituximab for R/R FL.
Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.
The OSUCCC – James announces the following awards, honors, grants and more that were recently given to the organization, teams or individuals.
Annals of Surgical Oncology – For operable triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), clinical prognostication and postoperative decision-making relies…
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Immunology researcher Susan Bullman, Ph.D., talks about her research and what excites her about working at MD Anderson.
Platinum-based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, defined as lasting at least 3 months.
The European Commission has approved serplulimab in combination with carboplatin and etoposide for the frontline treatment of adult patients with ES-SCLC.
